11 years of historical data (2014–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Abivax S.A. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9.6B | $461M | $461M | — | — | — | — | — | — | — | — |
| Enterprise Value | $9.5B | $415M | $267M | — | — | — | — | — | — | — | — |
| P/E Ratio → | -36.72 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 753.36 | 42.76 | 99.72 | — | — | — | — | — | — | — | — |
| P/B Ratio | 159.73 | 11.37 | 2.35 | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 38.42 | 57.76 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Abivax S.A. earns an operating margin of -1602.9%. Operating margins have compressed from -1414.7% to -1602.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -149.0% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 99.0% | 97.6% | -321.6% | -53601.6% | -1409300.0% | -277.8% | -60.0% | -11431.5% | -721.4% |
| Operating Margin | -1602.9% | -1602.9% | -2756.5% | -1414.7% | -111891.9% | -60330.2% | -1664800.0% | -106155.6% | -141500.0% | -14359.1% | -43464.3% |
| Net Profit Margin | -1633.1% | -1633.1% | -3197.1% | -1325.3% | -114735.1% | -59604.8% | -1531700.0% | -87905.6% | -112230.0% | -11266.1% | -37985.7% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -149.0% | -149.0% | -145.4% | -366.8% | -193.7% | -205.8% | -115.1% | -38.2% | -21.4% | -22.3% | -30.2% |
| ROA | -66.2% | -66.2% | -73.4% | -65.7% | -47.0% | -61.0% | -57.9% | -29.3% | -19.6% | -20.9% | -27.9% |
| ROIC | — | — | -888.2% | -268.0% | -157.3% | -109.3% | -74.4% | -34.2% | -22.2% | -28.5% | -33.5% |
| ROCE | -98.5% | -98.5% | -96.9% | -128.3% | -64.3% | -83.3% | -78.4% | -40.7% | -26.8% | -28.1% | -33.6% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $144M exceeds total debt of $97M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.40 | 2.40 | 0.30 | 5.45 | 1.99 | 1.90 | 1.12 | 0.31 | — | 0.01 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.15 | -0.99 | 1.70 | -0.35 | 0.26 | 0.59 | 0.08 | -0.04 | -0.13 | -0.34 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -41.33 | -41.33 | -9.21 | -9.34 | -11.64 | -18.43 | -20.99 | -40.74 | — | -434.19 | -108.66 |
Net cash position: cash ($144M) exceeds total debt ($97M)
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.84x means Abivax S.A. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.70x to 1.84x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.84 | 1.84 | 3.25 | 0.70 | 2.33 | 1.94 | 1.47 | 2.47 | 3.84 | 7.85 | 11.59 |
| Quick Ratio | 1.84 | 1.84 | 3.25 | 0.70 | 2.21 | 1.94 | 1.38 | 2.47 | 3.80 | 7.83 | 11.56 |
| Cash Ratio | 1.55 | 1.55 | 2.96 | 0.52 | 1.88 | 1.51 | 0.79 | 1.53 | 3.13 | 6.48 | 10.51 |
| Asset Turnover | — | 0.05 | 0.01 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.04 | — | — | — | 0.04 | — | 24.47 | — | 72.90 | 281.63 | 2.95 |
| Days Sales Outstanding | — | 529.74 | 1508.58 | 662.30 | 82263.11 | 46580.95 | 999999.00 | 157619.17 | 133115.50 | 13803.90 | 33971.07 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Abivax S.A. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $63M | $43M | $19M | $15M | $14M | $12M | $10M | $10M | $10M | $10M |
Compare ABVX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ABVXYou | $10B | -36.7 | — | — | 100.0% | -1602.9% | -149.0% | — | — |
| ARGX | $47B | 60.0 | — | — | 89.6% | -1.0% | 17.4% | -0.5% | — |
| CANF | $14B | -4.4 | — | — | 100.0% | -1206.2% | -134.9% | -448.3% | — |
| AKTX | $13B | -0.0 | — | — | — | — | -179.9% | -172.5% | — |
| RAPT | $8B | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
| KYMR | $7B | -24.8 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| PTGX | $6B | -44.9 | — | 99.9 | — | — | -20.2% | -21.8% | — |
| IMVT | $6B | -10.2 | — | — | — | — | -62.5% | — | — |
| TGTX | $5B | 200.6 | 114.4 | — | 88.3% | 12.7% | 12.2% | 13.3% | 6.0 |
| APGE | $4B | -21.2 | — | — | — | — | -33.2% | -38.3% | — |
| KNSA | $3B | 59.3 | 41.0 | 133.6 | — | 11.4% | 23.6% | 17.1% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 11 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ABVX stacks up against sector leader argenx SE.
Start ComparisonAbivax S.A.'s current P/E ratio is -36.7x. This places it at the 50th percentile of its historical range.
Abivax S.A.'s return on equity (ROE) is -149.0%. The historical average is -118.4%.
Based on historical data, Abivax S.A. is trading at a P/E of -36.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Abivax S.A. has 100.0% gross margin and -1602.9% operating margin.